RNXT (RenovoRx) Total Assets : $10.03 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Total Assets?

RenovoRx's Total Assets for the quarter that ended in Sep. 2024 was $10.03 Mil.

During the past 12 months, RenovoRx's average Total Assets Growth Rate was 59.70% per year. During the past 3 years, the average Total Assets Growth Rate was 35.00% per year.

During the past 5 years, RenovoRx's highest 3-Year average Total Assets Growth Rate was 70.70%. The lowest was 35.00%. And the median was 52.85%.

Total Assets is connected with ROA %. RenovoRx's annualized ROA % for the quarter that ended in Sep. 2024 was -89.71%. Total Assets is also linked to Revenue through Asset Turnover. RenovoRx's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

RenovoRx Total Assets Historical Data

The historical data trend for RenovoRx's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Total Assets Chart

RenovoRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

2.27

1.91

16.29

7.27

1.47

RenovoRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															3.52	1.47	4.79	12.00	10.03

RenovoRx Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

RenovoRx's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-3	+	4.466
	=	1.47

RenovoRx's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	7.071	+	2.96
	=	10.03

RenovoRx (NAS:RNXT) Total Assets Explanation

Total Assets is connected with ROA %.

RenovoRx's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-9.884	/	( (12.004	+	10.031)	/ 2 )
	=	-9.884	/	11.0175
	=	-89.71 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

RenovoRx's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (12.004	+	10.031)	/ 2 )
=	0	/	11.0175
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

RenovoRx Total Assets Related Terms

Thank you for viewing the detailed overview of RenovoRx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovoRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022

Website

https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Executives

Angela Nelms	officer: Chief Operating Officer	C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers	officer: Chief Financial Officer	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah	director, officer: Chief Medical Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai	director, officer: Chief Executive Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West	10 percent owner	PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman	officer: Chief Financial Officer	65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners	officer: Chief Financial Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303